TAC1 and injury: Unlike relcovaptan, tolvaptan affected the ACE inhibitor pathway, which is linked to increased immune reactivity and worsened neuronal damage through substance P degradation after brain injury, thereby exacerbating neuronal damage and motor deficits [70].